The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The complement component C5a and its receptors, C5aR1 and C5aR2, are central to the orchestration of innate immunity. C5a is a potent anaphylatoxin generated during complement activation, acting as a ...
Individuals who develop antibodies against the GluN1 subunit of NMDA receptors can develop NMDA receptor encephalitis (NMDARE), which can lead to psychosis, cognitive deficits and movement disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback